Image

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

Recruiting
9 - 21 years of age
Both
Phase 3

Powered by AI

Overview

The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E. coli (STEC) infection in children and adolescents when compared with traditional approaches (conservative fluid management).

Description

The hemolytic uremic syndrome (HUS) is the most serious complication of high-risk Shiga toxin-producing Escherichia coli (STEC) infection and the most common cause of acquired acute kidney injury in otherwise healthy children. HUS develops in up to 20% of children following STEC infection, 60% of whom require temporary renal replacement therapy (RRT); an additional 50% develop serious extrarenal complications. Although mortality from acute HUS is low (1-3%), it has remained constant for three decades and approximately 30% of HUS survivors experience long-term sequelae, chiefly chronic kidney disease, hypertension, and diabetes. There have been only three relatively small, randomized trials to prevent progression to HUS and/or to reduce kidney injury once HUS is established; none have demonstrated benefits, and none have been performed since 1999.

Recent cohort studies suggest that early intravascular volume expansion (hyperhydration) in STEC infected children could be nephroprotective if and when HUS occurs. However, more evidence is needed before hyperhydration supplants traditional 'wait and see' (i.e., conservative fluid management) reactive care approaches which focus on outpatient care and minimizing intravenous fluid administration to avoid fluid overload in children who do develop HUS. Here, we will confirm or refute the hypothesis that aggressive volume expansion, administered early in STEC infected children, is associated with better renal outcomes and fewer adverse events than conservative management by accomplishing three Specific Aims: (1) Determine the effectiveness of hyperhydration in decreasing the prevalence of Major Adverse Kidney Events by 30 days (defined as death, RRT, or sustained loss of kidney function at 30 days) in STEC-infected children versus conservative fluid management; (2) Determine the effectiveness and safety of hyperhydration in decreasing HUS and life-threatening, extrarenal complications in STEC-infected children versus conservative fluid management; (3) Create a biorepository that will be linked to our clinical data to identify prognostic biomarkers and therapeutic targets in STEC-infected children.

Eligibility

Inclusion Criteria:

        In order to be eligible to participate in this study (i.e., to be enrolled in the relevant
        institutional clinical care pathway), an individual must meet all of the following
        criteria:
          1. Aged 9.0 months to <21 years at the time of informed consent.
          2. Evidence of high-risk STEC infecting pathogen defined by any of the following:
               1. Bloody diarrhea within the preceding 7 days
                    -  Positive STEC culture OR
                    -  Positive antigen/polymerase chain reaction test for toxin/gene type not
                       otherwise specified OR
               2. Bloody or Non-bloody diarrhea within the preceding 7 days
                  •Presumptive diagnosis of HUS
                    -  (meeting all 3 HUS criteria - anemia, thrombocytopenia, and renal
                       insufficiency) OR
               3. Non-bloody or no diarrhea
                    -  Positive STEC culture for high-risk strain (i.e., O103, O104, O111, O113,
                       O121, O145 or O157) OR
                    -  Positive antigen/polymerase chain reaction test Stx2 toxin/gene
        Exclusion Criteria:
        All individuals meeting any of the exclusion criteria at baseline will be excluded from
        study participation.
          1. Presence of Advanced HUS defined by:
               1. Hematocrit <30% AND
               2. Platelet count <150 x 103/mm3 AND
               3. Creatinine > 2.0 mg/dL (177 µmol/L)
                    -  The presence of only 1 or 2 of these criteria will not result in patient
                       exclusion, regardless of how close the 3rd criterion is to meeting the
                       exclusion criteria.
          2. Prior episode of HUS or diagnosis of atypical HUS.
          3. Chronic disease limiting fluid volumes administered (e.g. impaired renal, liver, or
             cardiac function, chronic lung disease).
          4. Evidence of anuria (i.e., no urine output for > 24 hours).
          5. Hypoxemia requiring oxygen therapy
          6. Hypertensive emergency
          7. Greater than or equal to 10 days since onset of diarrhea or if no diarrhea then the
             onset of other symptoms.
          8. Patients with known pregnancy
          9. Patients or caregivers with language barriers impairing appropriate conduct of the
             study protocol.

Study details

Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome

NCT05219110

University of Calgary

27 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.